Skip to main navigation Skip to search Skip to main content

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

  • Jennie G. Pouget
  • , Vanessa F. Gonçalves
  • , Erika L. Nurmi
  • , Christopher P Laughlin
  • , Karyn S. Mallya
  • , James T. McCracken
  • , Michael G. Aman
  • , Christopher J. McDougle
  • , Lawrence Scahill
  • , Virginia L. Misener
  • , Arun K. Tiwari
  • , Clement C. Zai
  • , Eva J. Brandl
  • , Daniel Felsky
  • , Amy Q. Leung
  • , Jeffrey A. Lieberman
  • , Herbert Y. Meltzer
  • , Steven G. Potkin
  • , Charlotte Niedling
  • , Werner Steimer
  • Stefan Leucht, Jo Knight, Daniel J. Müller, James L. Kennedy
  • Centre for Addiction and Mental Health
  • University of Toronto Faculty of Medicine
  • University of Toronto
  • University of California
  • Ohio State University
  • Massachusetts General Hospital
  • Emory University School of Medicine
  • Charité – Universitätsmedizin Berlin
  • Vagelos College of Physicians and Surgeons
  • New York State Psychiatric Institute
  • Northwestern University Feinberg School of Medicine
  • University of California, Irvine
  • Technical University of Munich

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Aim: TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain. Patients & methods: We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119). Results: TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10-3), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10-3) and RUPP samples (p = 2.76 × 10-4). Conclusion: Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect. Original submitted 20 August 2014; Revision submitted 3 November 201.

Original languageEnglish
Pages (from-to)5-22
Number of pages18
JournalPharmacogenomics
Volume16
Issue number1
DOIs
StatePublished - 1 Jan 2015

Keywords

  • SLC25A4
  • TSPO
  • adenine nucleotide translocator
  • antipsychotic
  • genetics
  • mitochondria
  • peripheral benzodiazepine receptor
  • pharmacogenomics
  • schizophrenia
  • translocator protein-18 kDa
  • weight gain

Fingerprint

Dive into the research topics of 'Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes'. Together they form a unique fingerprint.

Cite this